Under Act 17, part 2 in executive order no. 226 dated March 15, 2007 on reporting obligations, BioPorto A/S hereby announces that the company's total share capital amounts to DKK 114,907,872 divided into shares of DKK 3.00 each, equivalent of 38,302,624 votes. BioPorto has ended the classification of A and B shares after which all shares belong to the same share class with the same rights. The 20,000 A-shares have thus been admitted to trading and official listing. New short name: BIOPOR For further information please contact: Christina Tønnesen, Investor Relations Tel. +45 45 29 00 34, e-mail info@bioporto.com
Recommended Reading
-
April 8, 2026 Company Announcement No. 7 BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC COPENHAGEN, DENMARK and BOSTON, MA, USA, April 8, 2026 –...
Read More -
March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 –...
Read More